To address this question we analyzed data for 84 consecutive patients with 86 lesions undergoing intravascular ultrasound guided stent implantation. Noncompliant or semicompliant balloons were used with an initial inflation pressure < 15 atmospheres (mean 12 ± 2 atmospheres) and final inflation pressure of ≥ 15 atmospheres (mean 18 ± 1 atmospheres) without changing the balloon size. Mean balloon size was 3.5 ± 0.4 mm and B/V 1.13 ± 0.16. The tightest stent lumen cross sectional area increased from (6.06 ± 1.66 mm^2) at first inflation to (7.58 ± 2.06 mm^2) at final inflation ($p < 0.0001$). The final cross sectional area achieved was larger than the distal reference lumen cross sectional area 7.06 ± 2.89 mm^2 (Figure 1). No vessel perforation occurred in this cohort of patients. This retrospective analysis illustrates that a mean inflation pressure of 18 atmospheres and a mean B/V ratio 1 : 1 could be a safe and effective strategy to optimize stent expansion.

Does Post Procedure Antiplatelet Regimen Make a Difference? Although optimal stent expansion remains the single most important factor in reducing stent thrombosis, the appropriate post stent pharmacological regimen is still the subject of ongoing investigation and controversy. The issue is whether treatment with ticlopidine with adjunctive aspirin provides additive benefit over aspirin therapy alone after optimal stent expansion. There is an abundance of clinical evidence that supports the efficacy of ticlopidine based antiplatelet regimen after stent implantation.[12-14] However, there is minimal comparative clinical data to support the increased efficacy of this regimen compared to aspirin in an era of optimal stent implantation. We recently published a prospective randomized trial[23] involving 226 patients undergoing intravascular ultrasound guided coronary stenting. One hundred and three patients were randomized to aspirin alone and 123 patients to a combination of aspirin and ticlopidine. At 1 month the rate of stent thrombosis was 2.9% in the aspirin only group and 0.8% in the ticlopidine–aspirin group ($p = 0.2$). Cumulative major clinical events after successful stenting occurred in 3.9% of patients in the aspirin group and in 0.8% in the combined ticlopidine–aspirin group ($p = 0.1$). There were no medication side effects in the aspirin group; in the combined group, medication side effects occurred in 3 patients ($p = 0.2$)

The STARS (Stent Anticoagulation Regimen Study) trial[24] will provide further information on this issue. This randomized trial with over 1600 patients will evaluate the comparative benefit of three post stent drug regimens: aspirin and low dose warfarin; aspirin and ticlopidine; aspirin alone.

CONCLUSIONS

After nearly a decade of clinical investigation and use, the community of interventional cardiologists has come to agreement on the issue of stent thrombosis. It is recognized that stent thrombosis is, in large part, an event triggered by stent underexpansion and/or inflow and outflow obstruction. Therefore, it is of crucial importance to follow a good technique and to thrive to achieve the best results possible. However, we do recognize that controversy continues as to which is the best and most cost–effective technique to document achievement of optimal stent implantation. This issue awaits the results of ongoing prospective randomized clinical trials.

REFERENCES

1. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute or threatened closure complicating percutaneous transluminal coronary angioplasty. *Circulation* 1992;85:916-927.
2. Fischman D, Leon M, Baim D, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med* 1994:496-501.
3. Serruys P, Jaeger P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J Med* 1994;331:489-495.
4. Nakamura S, Colombo A, Gaglione S, et al. Intracoronary ultrasound observations during stent implantation. *Circulation* 1994;89:2026-2034.
5. Goldberg SL, Colombo A, Nakamura S, et al. The benefit of intracoronary ultrasound in the deployment of Palmaz–Schatz stents. *J Am Coll Cardiol* 1994;24:996-1003.
6. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-1688.
7. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 1987;316:701-706.
8. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow–up after placement of a self–expanding coronary artery stent. *N Engl J Med* 1991;324:13-17.
9. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz–Schatz coronary stent: Initial results of a multicenter study. *Circulation* 1991;83:148-161.
10. Herrman NC, Buchbinder M, Clemen MW, et al. Emergent use of balloon expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. *Circulation* 1992;86:812-819.
11. George BS, Voorhees WD, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threat-

ened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. *J Am Coll Cardiol* 1993;22:135-143.

12. Morice MC. Advances in post stenting medication protocol. *J Invas Cardiol* 1995;7:32A-35A.
13. Barragan P, Silverstri M, Sainsous J, et al. Prevention of subacute occlusion after coronary stenting with ticlopidine regimen without intravascular ultrasound guided stenting. *J Am Coll Cardiol* 1995;25:182A.
14. Goods CM, Al-Shaibi KF, Dean LS, et al. Is ticlopidine a necessary component of antiplatelet regimen following coronary artery stenting? *J Am Coll Cardiol* 1996;March special issue:137A.
15. Agrawal S, Ho D, Liu M, et al. Predictors of thrombotic complications after placement of the flexible coil stent. *Am J Cardiol* 1994;73:1216-1221.
16. Nath C, Muller D, Ellis S, et al. Thrombosis of a flexible coil coronary stent: Frequency predictors and clinical outcome. *J Am Coll Cardiol* 1993;21:622-627.
17. Russo RJ, Teirstein PS, et al. Angiography versus intravascular ultrasound-directed stent placement. *J Am Coll Cardiol* 1996;March special issue:306A.
18. Hall P, Nakamura S, Maiello L, et al. Clinical and angiographic outcome after Palmaz-Schatz stent implantation guided by intravascular ultrasound. *J Invas Cardiol* 1995;7:12A-22A.
19. Blasini R, Mudra H, Schuhlen H, et al. Intravascular ultrasound guided optimized emergency coronary Palmaz-Schatz stent placement without post procedural systemic anticoagulation. *J Am Coll Cardiol* 1995;25:182A.
20. Painter J, Mintz G, Wong C, et al. Intravascular ultrasound assessment of biliary stent implantation in saphenous vein graft. *Am J Cardiol* 1995;75:731-734.
21. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new devices era. Incidence, classification, management and outcome. *Circulation* 1994;90:2725-2730.
22. Alfonso F, Macaya C, Goicolea J, et al. Determinants of coronary compliance in patients with coronary artery disease: An intravascular ultrasound study. *J Am Coll Cardiol* 1994;23:879-884.
23. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation* 1996;93:215-222.
24. Schomig A, Schuhlen H, Blasini R, et al. Anticoagulation versus antiplatelet therapy after intracoronary Palmaz-Schatz placement: A prospective randomized trial. *Circulation* 1995;92:I-280.

To address this question we analyzed data for 84 consecutive patients with 86 lesions undergoing intravascular ultrasound guided stent implantation. Noncompliant or semicompliant balloons were used with an initial inflation pressure < 15 atmospheres (mean 12 ± 2 atmospheres) and final inflation pressure of ≥ 15 atmospheres (mean 18 ± 1 atmospheres) without changing the balloon size. Mean balloon size was 3.5 ± 0.4 mm and B/V 1.13 ± 0.16. The tightest stent lumen cross sectional area increased from (6.06 ± 1.66 mm^2) at first inflation to (7.58 ± 2.06 mm^2) at final inflation ($p < 0.0001$). The final cross sectional area achieved was larger than the distal reference lumen cross sectional area 7.06 ± 2.89 mm^2 (Figure 1). No vessel perforation occurred in this cohort of patients. This retrospective analysis illustrates that a mean inflation pressure of 18 atmospheres and a mean B/V ratio 1 : 1 could be a safe and effective strategy to optimize stent expansion.

Does Post Procedure Antiplatelet Regimen Make a Difference? Although optimal stent expansion remains the single most important factor in reducing stent thrombosis, the appropriate post stent pharmacological regimen is still the subject of ongoing investigation and controversy. The issue is whether treatment with ticlopidine with adjunctive aspirin provides additive benefit over aspirin therapy alone after optimal stent expansion. There is an abundance of clinical evidence that supports the efficacy of ticlopidine based antiplatelet regimen after stent implantation.[12-14] However, there is minimal comparative clinical data to support the increased efficacy of this regimen compared to aspirin in an era of optimal stent implantation. We recently published a prospective randomized trial[23] involving 226 patients undergoing intravascular ultrasound guided coronary stenting. One hundred and three patients were randomized to aspirin alone and 123 patients to a combination of aspirin and ticlopidine. At 1 month the rate of stent thrombosis was 2.9% in the aspirin only group and 0.8% in the ticlopidine–aspirin group ($p = 0.2$). Cumulative major clinical events after successful stenting occurred in 3.9% of patients in the aspirin group and in 0.8% in the combined ticlopidine–aspirin group ($p = 0.1$). There were no medication side effects in the aspirin group; in the combined group, medication side effects occurred in 3 patients ($p = 0.2$)

The STARS (Stent Anticoagulation Regimen Study) trial[24] will provide further information on this issue. This randomized trial with over 1600 patients will evaluate the comparative benefit of three post stent drug regimens: aspirin and low dose warfarin; aspirin and ticlopidine; aspirin alone.

CONCLUSIONS

After nearly a decade of clinical investigation and use, the community of interventional cardiologists has come to agreement on the issue of stent thrombosis. It is recognized that stent thrombosis is, in large part, an event triggered by stent underexpansion and/or inflow and outflow obstruction. Therefore, it is of crucial importance to follow a good technique and to thrive to achieve the best results possible. However, we do recognize that controversy continues as to which is the best and most cost–effective technique to document achievement of optimal stent implantation. This issue awaits the results of ongoing prospective randomized clinical trials.

REFERENCES

1. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute or threatened closure complicating percutaneous transluminal coronary angioplasty. *Circulation* 1992;85:916-927.
2. Fischman D, Leon M, Baim D, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med* 1994:496-501.
3. Serruys P, Jaeger P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J Med* 1994;331:489-495.
4. Nakamura S, Colombo A, Gaglione S, et al. Intracoronary ultrasound observations during stent implantation. *Circulation* 1994;89:2026-2034.
5. Goldberg SL, Colombo A, Nakamura S, et al. The benefit of intracoronary ultrasound in the deployment of Palmaz–Schatz stents. *J Am Coll Cardiol* 1994;24:996-1003.
6. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-1688.
7. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 1987;316:701-706.
8. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow–up after placement of a self–expanding coronary artery stent. *N Engl J Med* 1991;324:13-17.
9. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz–Schatz coronary stent: Initial results of a multicenter study. *Circulation* 1991;83:148-161.
10. Herrman NC, Buchbinder M, Clemen MW, et al. Emergent use of balloon expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. *Circulation* 1992;86:812-819.
11. George BS, Voorhees WD, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threat-

ened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. *J Am Coll Cardiol* 1993;22:135-143.
12. Morice MC. Advances in post stenting medication protocol. *J Invas Cardiol* 1995;7:32A-35A.
13. Barragan P, Silverstri M, Sainsous J, et al. Prevention of subacute occlusion after coronary stenting with ticlopidine regimen without intravascular ultrasound guided stenting. *J Am Coll Cardiol* 1995;25:182A.
14. Goods CM, Al-Shaibi KF, Dean LS, et al. Is ticlopidine a necessary component of antiplatelet regimen following coronary artery stenting? *J Am Coll Cardiol* 1996;March special issue:137A.
15. Agrawal S, Ho D, Liu M, et al. Predictors of thrombotic complications after placement of the flexible coil stent. *Am J Cardiol* 1994;73:1216-1221.
16. Nath C, Muller D, Ellis S, et al. Thrombosis of a flexible coil coronary stent: Frequency predictors and clinical outcome. *J Am Coll Cardiol* 1993;21:622-627.
17. Russo RJ, Teirstein PS, et al. Angiography versus intravascular ultrasound-directed stent placement. *J Am Coll Cardiol* 1996;March special issue:306A.
18. Hall P, Nakamura S, Maiello L, et al. Clinical and angiographic outcome after Palmaz-Schatz stent implantation guided by intravascular ultrasound. *J Invas Cardiol* 1995;7:12A-22A.
19. Blasini R, Mudra H, Schuhlen H, et al. Intravascular ultrasound guided optimized emergency coronary Palmaz-Schatz stent placement without post procedural systemic anticoagulation. *J Am Coll Cardiol* 1995;25:182A.
20. Painter J, Mintz G, Wong C, et al. Intravascular ultrasound assessment of biliary stent implantation in saphenous vein graft. *Am J Cardiol* 1995;75:731-734.
21. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new devices era. Incidence, classification, management and outcome. *Circulation* 1994;90:2725-2730.
22. Alfonso F, Macaya C, Goicolea J, et al. Determinants of coronary compliance in patients with coronary artery disease: An intravascular ultrasound study. *J Am Coll Cardiol* 1994;23:879-884.
23. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation* 1996;93:215-222.
24. Schomig A, Schuhlen H, Blasini R, et al. Anticoagulation versus antiplatelet therapy after intracoronary Palmaz-Schatz placement: A prospective randomized trial. *Circulation* 1995;92:I-280.

To address this question we analyzed data for 84 consecutive patients with 86 lesions undergoing intravascular ultrasound guided stent implantation. Noncompliant or semicompliant balloons were used with an initial inflation pressure < 15 atmospheres (mean 12 ± 2 atmospheres) and final inflation pressure of ≥ 15 atmospheres (mean 18 ± 1 atmospheres) without changing the balloon size. Mean balloon size was 3.5 ± 0.4 mm and B/V 1.13 ± 0.16. The tightest stent lumen cross sectional area increased from (6.06 ± 1.66 mm^2) at first inflation to (7.58 ± 2.06 mm^2) at final inflation ($p < 0.0001$). The final cross sectional area achieved was larger than the distal reference lumen cross sectional area 7.06 ± 2.89 mm^2 (Figure 1). No vessel perforation occurred in this cohort of patients. This retrospective analysis illustrates that a mean inflation pressure of 18 atmospheres and a mean B/V ratio 1 : 1 could be a safe and effective strategy to optimize stent expansion.

Does Post Procedure Antiplatelet Regimen Make a Difference? Although optimal stent expansion remains the single most important factor in reducing stent thrombosis, the appropriate post stent pharmacological regimen is still the subject of ongoing investigation and controversy. The issue is whether treatment with ticlopidine with adjunctive aspirin provides additive benefit over aspirin therapy alone after optimal stent expansion. There is an abundance of clinical evidence that supports the efficacy of ticlopidine based antiplatelet regimen after stent implantation.[12-14] However, there is minimal comparative clinical data to support the increased efficacy of this regimen compared to aspirin in an era of optimal stent implantation. We recently published a prospective randomized trial[23] involving 226 patients undergoing intravascular ultrasound guided coronary stenting. One hundred and three patients were randomized to aspirin alone and 123 patients to a combination of aspirin and ticlopidine. At 1 month the rate of stent thrombosis was 2.9% in the aspirin only group and 0.8% in the ticlopidine–aspirin group ($p = 0.2$). Cumulative major clinical events after successful stenting occurred in 3.9% of patients in the aspirin group and in 0.8% in the combined ticlopidine–aspirin group ($p = 0.1$). There were no medication side effects in the aspirin group; in the combined group, medication side effects occurred in 3 patients ($p = 0.2$)

The STARS (Stent Anticoagulation Regimen Study) trial[24] will provide further information on this issue. This randomized trial with over 1600 patients will evaluate the comparative benefit of three post stent drug regimens: aspirin and low dose warfarin; aspirin and ticlopidine; aspirin alone.

CONCLUSIONS

After nearly a decade of clinical investigation and use, the community of interventional cardiologists has come to agreement on the issue of stent thrombosis. It is recognized that stent thrombosis is, in large part, an event triggered by stent underexpansion and/or inflow and outflow obstruction. Therefore, it is of crucial importance to follow a good technique and to thrive to achieve the best results possible. However, we do recognize that controversy continues as to which is the best and most cost–effective technique to document achievement of optimal stent implantation. This issue awaits the results of ongoing prospective randomized clinical trials.

REFERENCES

1. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute or threatened closure complicating percutaneous transluminal coronary angioplasty. *Circulation* 1992;85:916-927.
2. Fischman D, Leon M, Baim D, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med* 1994:496-501.
3. Serruys P, Jaeger P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J Med* 1994;331:489-495.
4. Nakamura S, Colombo A, Gaglione S, et al. Intracoronary ultrasound observations during stent implantation. *Circulation* 1994;89:2026-2034.
5. Goldberg SL, Colombo A, Nakamura S, et al. The benefit of intracoronary ultrasound in the deployment of Palmaz–Schatz stents. *J Am Coll Cardiol* 1994;24:996-1003.
6. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-1688.
7. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 1987;316:701-706.
8. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow–up after placement of a self–expanding coronary artery stent. *N Engl J Med* 1991;324:13-17.
9. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz–Schatz coronary stent: Initial results of a multicenter study. *Circulation* 1991;83:148-161.
10. Herrman NC, Buchbinder M, Clemen MW, et al. Emergent use of balloon expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. *Circulation* 1992;86:812-819.
11. George BS, Voorhees WD, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threat-

ened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. *J Am Coll Cardiol* 1993;22:135-143.

12. Morice MC. Advances in post stenting medication protocol. *J Invas Cardiol* 1995;7:32A-35A.
13. Barragan P, Silverstri M, Sainsous J, et al. Prevention of subacute occlusion after coronary stenting with ticlopidine regimen without intravascular ultrasound guided stenting. *J Am Coll Cardiol* 1995;25:182A.
14. Goods CM, Al-Shaibi KF, Dean LS, et al. Is ticlopidine a necessary component of antiplatelet regimen following coronary artery stenting? *J Am Coll Cardiol* 1996;March special issue:137A.
15. Agrawal S, Ho D, Liu M, et al. Predictors of thrombotic complications after placement of the flexible coil stent. *Am J Cardiol* 1994;73:1216-1221.
16. Nath C, Muller D, Ellis S, et al. Thrombosis of a flexible coil coronary stent: Frequency predictors and clinical outcome. *J Am Coll Cardiol* 1993;21:622-627.
17. Russo RJ, Teirstein PS, et al. Angiography versus intravascular ultrasound-directed stent placement. *J Am Coll Cardiol* 1996;March special issue:306A.
18. Hall P, Nakamura S, Maiello L, et al. Clinical and angiographic outcome after Palmaz-Schatz stent implantation guided by intravascular ultrasound. *J Invas Cardiol* 1995;7:12A-22A.
19. Blasini R, Mudra H, Schuhlen H, et al. Intravascular ultrasound guided optimized emergency coronary Palmaz-Schatz stent placement without post procedural systemic anticoagulation. *J Am Coll Cardiol* 1995;25:182A.
20. Painter J, Mintz G, Wong C, et al. Intravascular ultrasound assessment of biliary stent implantation in saphenous vein graft. *Am J Cardiol* 1995;75:731-734.
21. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new devices era. Incidence, classification, management and outcome. *Circulation* 1994;90:2725-2730.
22. Alfonso F, Macaya C, Goicolea J, et al. Determinants of coronary compliance in patients with coronary artery disease: An intravascular ultrasound study. *J Am Coll Cardiol* 1994;23:879-884.
23. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation* 1996;93:215-222.
24. Schomig A, Schuhlen H, Blasini R, et al. Anticoagulation versus antiplatelet therapy after intracoronary Palmaz-Schatz placement: A prospective randomized trial. *Circulation* 1995;92:I-280.